skip to content

Shapiro, Charles L.

Overview
Works: 4 works in 14 publications in 1 language and 69 library holdings
Roles: Editor
Publication Timeline
Key
Publications about Charles L Shapiro
Publications by Charles L Shapiro
Most widely held works by Charles L Shapiro
New directions in breast cancer : research and therapeutics ( Book )
8 editions published in 1994 in English and held by 60 libraries worldwide
Late effects of treatment and survivorship issues in early-stage breast carcinoma ( Book )
2 editions published in 2003 in English and held by 5 libraries worldwide
The Effect of COX-2 Inhibitors on the Aromatase Gene (CYP19) Expression in Human Breast Cancer ( file )
3 editions published between 2002 and 2004 in English and held by 0 libraries worldwide
Aromatase (CYP-19) is responsible for estrogen biosynthesis within breast tumor tissue Aromatase and cyclooxygenase-2 (COX-2) are both overexpressed in human breast cancer, and increased levels of prostaglandin (PG) activates the CYP19 promotor and increases gene expression We hypothesize that celecoxib, a selective COX-2 inhibitor, will decrease PG, decrease the expression of CYP19, and reduce estrogen biosynthesis within tumor tissue To test this hypothesis, in DOD grant # DAMDl7-0l-0589, tumor tissue will be collected from breast cancer patients at the initial diagnosis, and again at the definitive surgery (lumpectomy or mastectomy) for breast cancer In the 10-14 day internal before the definitive surgery, patients will receive celecoxib and tissue samples collected before and after treatment with celecoxib will be evaluated for gene expression of COX-2 and CYP19 If our hypothesis is correct, then expression of the CYP19 gene will decrease in response to celecoxib This study will provide preliminary data to a) support a mechanism whereby COX-2 inhibitors decrease estrogen production within breast tumors by decreasing CYP19 expression; and b) provide the rationale for initiating larger chemoprevention and therapeutic trials of COX-2 inhibitors in high risk and breast cancer patients
The Effect of COX-2 Inhibitors on the Aromatase Gene (CYP19) Expression in Human Breast Cancer ( file )
1 edition published in 2006 in English and held by 0 libraries worldwide
Aromatase (CYP19) is responsible for estrogen biosynthesis, and CYP-19 and cyclooxygenase-2 (COX-2) are both overexpressed in human breast cancers. Prostaglandin activates the CYP19 promotor and increases gene expression therefore we hypothesized that celecoxib, a selective COX-2 inhibitor, will decrease PG and decrease the expression of CYP19. To test this hypothesis, celecoxib was administered to breast cancer patients after the initial core biopsy tumor tissue and then tumor tissue was collected at the definitive surgery on OSU protocol 0125. A total of 8 breast cancer patients were enrolled until December 20, 2004 when the cardiovascular risks associated with celecoxib were made public. Accrual was suspended and the restarted in July 2005 with a revised protocol and consent form describing the cardiovascular risks. The trial was closed November 13, 2006 due to lack of accrual. There were no adverse events recorded during celecoxib administration. With only 8/34 (23%) of patients enrolled, there have no analysis of gene expression of CYP19. This trial failed to accrue, in part, over concerns about the cardiovascular risks
 
Languages
English (14)
Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.